Lifecore Biomedical, Inc. revenue by segment LFCR

Lifecore Biomedical, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Contract Development And Manufacturing Organization at $17.8 million, 70% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Sep 30, 2025
Q4 FY2025
May 25, 2025
Q3 FY2025
Feb 23, 2025
Q2 FY2025
Nov 24, 2024
Q1 FY2025
Aug 25, 2024
Q4 FY2024
May 26, 2024
Revenue
119
25
34
31
36
35
33
25
38
Contract Development And Manufacturing Organization
—
18
-14.5%
share 70.2%
16
share 45.5%
22
+7.8%
share 69.9%
24
share 64.5%
21
share 59.1%
—
20
share 81.7%
—
HA Manufacturing
—
8
-47.5%
share 29.8%
19
share 54.5%
9
+106.9%
share 30.1%
13
share 35.5%
14
share 40.9%
—
5
share 18.3%
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LFCR (Nasdaq)
Fiscal year ends
May 25
Incorporated in
DE
Headquarters
Chaska, MN
SEC filer status
Accelerated filer, Smaller reporting company
SEC CIK
1005286
Former names
LANDEC CORP \CA\ (until Nov 7, 2022)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.